ClinicalTrials.gg
CompletedNCT03037437Updated Oct 21, 2026Results posted

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

A Phase 2 interventional study of Sorafenib (SOR) and Hydroxychloroquine (HCQ) in Hepatocellular Cancer, sponsored by The University of Texas Health Science Center at San Antonio. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by The University of Texas Health Science Center at San Antonio · Phase 2, Interventional, and Treatment

How we know

Updated Oct 21, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies testing sorafenib in Liver Neoplasms — none open to participants now, none under way, none of them phase 3. Sorafenib · Liver Neoplasms.

Enrollment
17th of 38
37 · median 28
Started
2017
with 1 other
Phase 2
14 of 38
none open now
Registered
37th of 38
by date

Among the 38 studies testing sorafenib in Liver Neoplasms, this one is the 17th largest by enrollment, is one of 2 that started in 2017, is one of 14 in phase 2, and was the 37th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

None of the 38 studies testing sorafenib in Liver Neoplasms is open now. The open studies under Liver Neoplasms, anywhere →

About sorafenib

Sorafenib: first FDA approval 2005 (NEXAVAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 38 studies testing sorafenib in Liver Neoplasms as a file.
02

Study summary

The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).

Read the detailed description

Phase 2 study with two cohorts:

Cohort 1: As second-line treatment, we will add HCQ to SOR dose the patient was tolerating at the time of progression.

Cohort 2: SOR-naïve patients receive SOR 400 mg by PO twice daily on Cycle1 Day1 (C1D1). On Cycle 1 Day 15, HCQ 400 mg PO daily will be started. In clinical practice, dose reduction of SOR may be required. On C1D15 SOR maybe kept as starting dose or reduced for toxicity. On Cycle 2 Day 1 of toxicity of HCQ and SOR will be assessed.

Each cycle is 28 days.

Blood samples will be collected at Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 2 Day 1 to assess for biomarkers.

Disease evaluation every 2 cycles.

Dose reductions due to adverse events are allowed for both sorafenib per standard of care and/or HCQ for grade 3 or more adverse event was related to study medication. Dose reductions are also permitted based on investigator clinical decision.

03

Conditions studied

  • Hepatocellular Cancer

Browse trials for

Keywords

  • Hepatocellular Cancer
  • Sorafenib
  • Hydroxychloroquine
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or histologically confirmed advanced or HCC. If no histological diagnosis, patient must have imaging studies compatible with HCC.
  • Age 18 years and above
  • performance status of 0 or 1
  • Not a candidate for curative treatments (i.e., resection, transplantation)
  • class A or B7 liver function
  • as defined by 1.1
  • Patients who received prior local therapy (e.g., TACE) are eligible.
  • Documented virology status of hepatitis, as confirmed by screening , anti-HBc, and/or anti-
  • > 3 months
  • For women who are not (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of . For men: agreement to use a barrier method of contraception during the treatment period
  • Hematologic, Biochemical, and Organ Function within 7 days prior to Cycle 1 Day 1: Granulocyte count > 1500/mm3, count > 75,000/ mm3, > 8 g/dL; Total \< 2.0; Albumin > 2.8g/dl; (SGOT) and ALT (SGPT) \< 5 x ; Serum creatinine\< 1.5 x ULN
  • Cohort 1 (with sorafenib): No previous systemic therapy including sorafenib or chemotherapy treatment. Previous TACE and local treatments are permitted.
  • Cohort 2 (on progression of sorafenib): Patients who have received prior sorafenib therapy for at least 4 weeks and has confirmation of disease progression on CT/MRI. Prior surgery or local therapy within 4 weeks prior to Cycle 1 Day 1, with the exception of palliative radiation therapy to the bone

Exclusion criteria

Exclusion Criteria:

  • Patients receiving prior therapy with HCQ.
  • Patients with uncontrolled . Patients with brain metastases must be asymptomatic and off for at least one week.
  • Due to risk of disease exacerbation, patients with psoriasis are ineligible unless the disease is well controlled, and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbations.
  • Patients with previously documented macular degeneration or or untreated diabetic retinopathy (stable retinopathy is allowed).
  • Patients may not be receiving any other agents.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ.
  • Patients requiring the use of enzyme-inducing anti-epileptic medication (phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine) are not eligible for entry into the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • > 500 milliseconds (ms) at baseline.
  • Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease. Patients with NG-tube, J-tube, or G-tube will not be allowed to participate.
  • Pregnant women are excluded from this study because sorafenib has the potential for teratogenic or abortifacient effects. For this reason, women of and men must also agree to use adequate (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation.
  • Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sorafenib, breastfeeding should be discontinued.
  • - No study specific procedures will be performed without a written and signed informed consent document. Patients who do not demonstrate the ability to understand or the willingness to sign the written informed consent document will be excluded from study entry.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    No prior systemic treatment

    Sorafenib (SOR)-naïve patients receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1). In clinical practice, dose reduction of SOR is often required. Therefore, on C1D15, the clinician will dose-reduce sorafenib based on toxicity and hydroxychloroquine (HCQ) 400 mg PO daily will be started. C2D1 of each cohort, toxicity of HCQ will be assessed. Dose reductions due to adverse events (AEs) to each agent are allowed for SOR per standard of care and/or HCQ for grade 3+ AE.

    Drug: Sorafenib (SOR) · Drug: Hydroxychloroquine (HCQ)

  • Experimental
    Progress on sorafenib

    As second-line treatment, we will add hydroxychloroquine (HCQ) to sorafenib (SOR) dose the patient was tolerating at the time of progression.

    Drug: Sorafenib (SOR) · Drug: Hydroxychloroquine (HCQ)

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Tumor Progression Evaluated Via Tumor Imaging

    Computerized axial tomography (CAT) Scan or Magnetic resonance imaging (MRI) will be done at Screening, then every other cycle and evaluated using RECIST version 1.1

    Time frame: From baseline to study completion, approximately 1 year

07

Results

Posted Oct 21, 2026

Participant flow

Participant flow — Overall Study
MilestoneNo Prior Systemic TreatmentCohort 2: Addition of HCQ
Started325
Completed cycle 1250
Completed20
Not completed305

Outcome measures

PrimaryTime to Tumor Progression Evaluated Via Tumor Imaging

Computerized axial tomography (CAT) Scan or Magnetic resonance imaging (MRI) will be done at Screening, then every other cycle and evaluated using RECIST version 1.1

Time frame:
From baseline to study completion, approximately 1 year
Reported as:
Mean · months
Time to Tumor Progression Evaluated Via Tumor Imaging
monthsNo Prior Systemic TreatmentCohort 2: Addition of HCQ
Time to Tumor Progression Evaluated Via Tumor Imaging8 (4.0 to 19.0)—

Adverse events

Collected over Through study completion, and average of 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
No Prior Systemic Treatment1/32 (3.1%)1/32 (3.1%)28/32 (87.5%)
Cohort 2: Addition of HCQ1/5 (20%)0/5 (0%)2/5 (40%)
Most frequent serious events
Most frequent serious events
EventNo Prior Systemic TreatmentCohort 2: Addition of HCQ
Myocardial infarctionCardiac disorders1/320/5
Most frequent other events
Showing 10 of 44
Most frequent other events
EventNo Prior Systemic TreatmentCohort 2: Addition of HCQ
Palmar-plantar erthrodysesthesia syndromeSkin and subcutaneous tissue disorders17/321/5
DiarrheaGastrointestinal disorders14/321/5
AnorexiaGastrointestinal disorders12/321/5
NauseaGastrointestinal disorders10/321/5
MucositisGastrointestinal disorders7/321/5
Abdominal PainGastrointestinal disorders3/321/5
AnxietyNervous system disorders0/321/5
FatigueGeneral disorders5/321/5
VomitingGastrointestinal disorders1/321/5
Weight LossMetabolism and nutrition disorders5/321/5

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)No Prior Systemic TreatmentCohort 2: Addition of HCQTotal
<=18 years000
Between 18 and 65 years25227
>=65 years7310
Sex: Female, Male
Sex: Female, Male(Participants)No Prior Systemic TreatmentCohort 2: Addition of HCQTotal
Female9110
Male23427
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)No Prior Systemic TreatmentCohort 2: Addition of HCQTotal
Hispanic or Latino28432
Not Hispanic or Latino415
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)No Prior Systemic TreatmentCohort 2: Addition of HCQTotal
United States32537
08

Study locations

1 site
  • University of Texas Health Cancer Center
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jun 2025, 100 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 73 non-industry phase 2 interventional studies under Liver Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 103. This study's 100 months is above that.

Counting every sponsor, half of 87 studies reached it within 57 months; a quarter within 37 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2017
First posted
Jan 31, 2017
StartActual
Feb 16, 2017
Primary completionActual
Jun 27, 2025
CompletionActual
Jun 27, 2025
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Enrollment
64→37
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedTime to tumor progression evaluated via tumor imagingTumor Progression Evaluated Via Tumor ImagingTime frame: Through study completion, an average of 1 year → From baseline to study completion, approximately 1 year
Oct 21, 2026
Documents
Show all 1 update
  1. Oct 21, 2026
    Results posted
    Enrollment 64→37
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedTime to tumor progression evaluated via tumor imagingTumor Progression Evaluated Via Tumor ImagingTime frame: Through study completion, an average of 1 year → From baseline to study completion, approximately 1 year
    + 4 other changes: index terms, verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03037437
Responsible party
Sukeshi Patel (Principal Investigator, The University of Texas Health Science Center at San Antonio) — Principal investigator
First posted
Jan 31, 2017
Start date
Feb 16, 2017
Primary completion
Jun 27, 2025
Completion
Jun 27, 2025
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

Sukeshi Patel Arora, MD
principal investigator · Cancer Therapy & Research Center University of Texas Health Science Center San Antonio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sorafenib · Hydroxychloroquine

Start the discussion